Antje M Richter (Antje Richter)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Topics

Tyrosine Kinase

Cell Proliferation

Top Venues

Clinical epigenetics

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Arroyo Villora, Paula Castellanos Silva, Tamara Zenz, Ji Sun Kwon, Nico Schlaudraff, Dafina Nitaj, Cornelia Meckbach, Reinhard H Dammann, Antje M Richter
Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function. Genes 15 (2) (2024)
Sarah Arroyo Villora, Paula Castellanos Silva, Tamara Zenz, Ji Sun Kwon, Nico Schlaudraff, Dafina Nitaj, Cornelia Meckbach, Reinhard H Dammann, Antje M Richter
Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function. Genes 15 (2) (2024)
Sarah Arroyo Villora, Paula Castellanos Silva, Tamara Zenz, Ji Sun Kwon, Nico Schlaudraff, Dafina Nitaj, Cornelia Meckbach, Reinhard H Dammann, Antje M Richter
Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function. Genes 15 (2) (2024)
Sarah Arroyo Villora, Paula Castellanos Silva, Tamara Zenz, Ji Sun Kwon, Nico Schlaudraff, Dafina Nitaj, Cornelia Meckbach, Reinhard H Dammann, Antje M Richter
Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function. Genes 15 (2) (2024)
Sarah Arroyo Villora, Paula Castellanos Silva, Tamara Zenz, Ji Sun Kwon, Nico Schlaudraff, Dafina Nitaj, Cornelia Meckbach, Reinhard H Dammann, Antje M Richter
Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function. Genes 15 (2) (2024)
Yassire Oubaddou, Mohamed Oukabli, Salma Fenniche, Abderrahim Elktaibi, Mohamed Reda Elochi, Abderrahmane Al Bouzidi, Zineb Qmichou, Nadia Dakka, Caroline Diorio, Antje M Richter, Youssef Bakri, Rabii Ameziane El Hassani
BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach. Genes 14 (9) (2023)
Michelle L Woods, Astrid Weiss, Anna M Sokol, Johannes Graumann, Thomas Boettger, Antje M Richter, Ralph Theo Schermuly, Reinhard H Dammann
Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner. Cancer gene therapy (2022)
Antje M Richter, Michelle L Woods, Miriam M Küster, Sara K Walesch, Thomas Braun, Thomas Boettger, Reinhard H Dammann
RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. Oncogene 39 (15) (2020)
Miriam M Küster, Marc A Schneider, Antje M Richter, Sarah Richtmann, Hauke Winter, Mark Kriegsmann, Soni Savai Pullamsetti, Thorsten Stiewe, Soni Savai Pullamsetti, Thomas Muley, Reinhard H Dammann
Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. Cancers 12 (12) (2020)
Verena Deutschmeyer, Janina Breuer, Sara K Walesch, Anna M Sokol, Johannes Graumann, Marek Bartkuhn, Thomas Boettger, Oliver Rossbach, Antje M Richter
Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. Clinical epigenetics 11 (1) (2019)
Antje M Richter, Steffen Kiehl, Nicole Köger, Janina Breuer, Thorsten Stiewe, Reinhard H Dammann
ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer. Clinical epigenetics 9 (2017)